Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Conditions:   Diffuse Large B-cell Lymphoma;   Acute Myeloid Leukemia;   Non-Hodgkin's Lymphoma Interventions:   Drug: Venetoclax;   Drug: Selinexor Sponsors:   Michael Byrne;   Karyopharm Therapeutics Inc;   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials